Clinical Trials Logo

Plaque Psoriasis clinical trials

View clinical trials related to Plaque Psoriasis.

Filter by:

NCT ID: NCT04908514 Completed - Plaque Psoriasis Clinical Trials

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Start date: May 7, 2021
Phase: Phase 2
Study type: Interventional

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

NCT ID: NCT04855721 Completed - Plaque Psoriasis Clinical Trials

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

INDUS-3
Start date: May 4, 2021
Phase: Phase 2
Study type: Interventional

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)

NCT ID: NCT04746911 Completed - Psoriasis Clinical Trials

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:

NCT ID: NCT04728360 Completed - Plaque Psoriasis Clinical Trials

Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Start date: July 6, 2021
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2206 with Stelara in patients with moderate to severe plaque psoriasis. The study is composed of a ≤ 28-day screening period, a 16-week initial treatment period (TP1), a 24-week secondary treatment period (TP2), a 12-week efficacy and safety follow-up period up to end-of-study visit, for a maximum total study duration of 56 weeks.

NCT ID: NCT04720105 Completed - Plaque Psoriasis Clinical Trials

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Start date: November 19, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet.

NCT ID: NCT04664153 Completed - Atopic Dermatitis Clinical Trials

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

EMPORIA
Start date: December 21, 2020
Phase: Phase 2
Study type: Interventional

This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.

NCT ID: NCT04655313 Completed - Psoriasis Clinical Trials

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:

NCT ID: NCT04607980 Completed - Plaque Psoriasis Clinical Trials

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Start date: November 11, 2020
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.

NCT ID: NCT04603027 Completed - Psoriasis Clinical Trials

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Start date: September 21, 2020
Phase: Phase 2
Study type: Interventional

This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.

NCT ID: NCT04595409 Completed - Plaque Psoriasis Clinical Trials

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

VESPUCCI
Start date: November 9, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.